Shareholder Alert: The Ademi Firm investigates whether Lisata Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders

Core Viewpoint - Ademi LLP is investigating Lisata Therapeutics Inc. for potential breaches of fiduciary duty and other legal violations related to its transaction with Kuva Labs Inc. [1] Group 1: Transaction Details - Lisata stockholders will receive $5.00 per share in cash plus one contingent value right per share, which could provide an additional $1.00 per share if a New Drug Application for certepetide is filed or accepted by the FDA within seven years of closing [1]. - The transaction agreement imposes significant penalties on Lisata for accepting competing bids, which raises concerns about the fairness of the deal for shareholders [1]. Group 2: Investigation Focus - The investigation is centered on the conduct of Lisata's board of directors and whether they are fulfilling their fiduciary duties to all shareholders [1]. - Ademi LLP specializes in shareholder litigation involving buyouts, mergers, and individual shareholder rights, indicating a focus on protecting shareholder interests [1].